S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
High oil prices help Saudi Aramco earn $88B in first half
Ship carrying grain for hungry Ethiopia leaves Ukraine
Saudi Aramco's profits already $88B as oil prices stay high
Sell every Stock except ONE (Ad)
Saudi oil company Aramco's half-year profits reach close to $88 billion after posting a 90% surge in second quarter
Average US gasoline price falls 45 cents to $4.10 per gallon
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
Sell every Stock except ONE (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
High oil prices help Saudi Aramco earn $88B in first half
Ship carrying grain for hungry Ethiopia leaves Ukraine
Saudi Aramco's profits already $88B as oil prices stay high
Sell every Stock except ONE (Ad)
Saudi oil company Aramco's half-year profits reach close to $88 billion after posting a 90% surge in second quarter
Average US gasoline price falls 45 cents to $4.10 per gallon
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
Sell every Stock except ONE (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
High oil prices help Saudi Aramco earn $88B in first half
Ship carrying grain for hungry Ethiopia leaves Ukraine
Saudi Aramco's profits already $88B as oil prices stay high
Sell every Stock except ONE (Ad)
Saudi oil company Aramco's half-year profits reach close to $88 billion after posting a 90% surge in second quarter
Average US gasoline price falls 45 cents to $4.10 per gallon
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
Sell every Stock except ONE (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
High oil prices help Saudi Aramco earn $88B in first half
Ship carrying grain for hungry Ethiopia leaves Ukraine
Saudi Aramco's profits already $88B as oil prices stay high
Sell every Stock except ONE (Ad)
Saudi oil company Aramco's half-year profits reach close to $88 billion after posting a 90% surge in second quarter
Average US gasoline price falls 45 cents to $4.10 per gallon
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
Sell every Stock except ONE (Ad)
NASDAQ:BDSI

BioDelivery Sciences International - BDSI Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range
$5.59
$5.60
50-Day Range
$5.54
$5.60
52-Week Range
$2.50
$5.62
Volume
2.09 million shs
Average Volume
3.34 million shs
Market Capitalization
$577.05 million
P/E Ratio
6.74
Dividend Yield
N/A
Price Target
$6.43

BioDelivery Sciences International MarketRank™ Forecast

Analyst Rating
Hold
2.17 Rating Score
Upside/​Downside
14.9% Upside
$6.43 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
-2.18
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
73.68%
From $0.38 to $0.66 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.05 out of 5 stars

Medical Sector

713th out of 1,135 stocks

Pharmaceutical Preparations Industry

363rd out of 557 stocks

BDSI stock logo

About BioDelivery Sciences International (NASDAQ:BDSI) Stock

BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products for chronic conditions in the United States and internationally. The company provides its products based on its patented BioErodible MucoAdhesive drug-delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; and Symproic, a peripherally acting mu-opioid receptor antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent opioid dosage escalation. The company also provides ELYXYB, a celecoxib oral solution for the treatment of migraine with or without aura in adults; and ONSOLIS, a fentanyl buccal soluble film for the management of breakthrough pain in cancer patients. BioDelivery Sciences International, Inc. was incorporated in 1997 and is headquartered in Raleigh, North Carolina. As of March 18, 2022, BioDelivery Sciences International, Inc. operates as a subsidiary of Collegium Pharmaceutical, Inc.

Receive BDSI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioDelivery Sciences International and its competitors with MarketBeat's FREE daily newsletter.

BDSI Stock News Headlines

Jim Cramer's Top Stock Picks: DF MNST BDSI
BioDelivery Sciences launches migraine therapy in U.S.
Should Value Investors Pick BioDelivery (BDSI) Stock Now?
BioDelivery Sciences International, Inc. (BDSI)
Tuesday 11/9 Insider Buying Report: BDSI, BALY
See More Headlines

Receive BDSI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioDelivery Sciences International and its competitors with MarketBeat's FREE daily newsletter.

BDSI Company Calendar

Last Earnings
11/02/2021
Today
8/14/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
Current Symbol
NASDAQ:BDSI
CUSIP
09060J10
Employees
200
Year Founded
1997

Price Target and Rating

Average Stock Price Forecast
$6.43
High Stock Price Forecast
$10.00
Low Stock Price Forecast
$4.50
Forecasted Upside/Downside
+14.9%
Consensus Rating
Hold
Rating Score (0-4)
2.17
Research Coverage
6 Analysts

Profitability

Net Income
$84.86 million
Pretax Margin
17.77%

Debt

Sales & Book Value

Annual Sales
$166.70 million
Cash Flow
$0.36 per share
Book Value
$1.90 per share

Miscellaneous

Free Float
92,927,000
Market Cap
$577.05 million
Optionable
Optionable
Beta
0.56

Social Links


Key Executives

  • Mr. Jeffrey Allen Bailey (Age 59)
    CEO & Director
    Comp: $599.96k
  • Mr. Scott M. Plesha (Age 57)
    Pres & Chief Commercial Officer
    Comp: $629.46k
  • Mr. James Vollins J.D. (Age 53)
    Gen. Counsel, Chief Compliance Officer & Corp. Sec.
    Comp: $586.68k
  • Dr. Thomas B. Smith FAAFP (Age 61)
    M.D., Chief Medical Officer
    Comp: $570.06k
  • Mr. John Golubieski (Age 57)
    CFO & Chief Accounting Officer
  • Mr. Joseph M. Lockhart
    Sr. VP of Operations
  • Mr. Kevin Ostrander
    Sr. VP of Bus. Devel.
  • Dr. Bill McCarberg
    Member of Scientific Advisory Board and Member of Arius Scientific Advisory Board
  • Dr. Arthur G. Lipman PharmD
    Member of Scientific Advisory Board and Member of Arius Scientific Advisory Board
  • Dr. Jeff Katz
    Member of Scientific Advisory Board and Member of Arius Scientific Advisory Board













BDSI Stock - Frequently Asked Questions

Should I buy or sell BioDelivery Sciences International stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioDelivery Sciences International in the last twelve months. There are currently 5 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" BDSI shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BDSI, but not buy additional shares or sell existing shares.
View BDSI analyst ratings
or view top-rated stocks.

What is BioDelivery Sciences International's stock price forecast for 2022?

6 Wall Street research analysts have issued 12 month target prices for BioDelivery Sciences International's shares. Their BDSI share price forecasts range from $4.50 to $10.00. On average, they anticipate the company's stock price to reach $6.43 in the next twelve months. This suggests a possible upside of 14.9% from the stock's current price.
View analysts price targets for BDSI
or view top-rated stocks among Wall Street analysts.

How were BioDelivery Sciences International's earnings last quarter?

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) released its quarterly earnings data on Tuesday, November, 2nd. The specialty pharmaceutical company reported $0.07 earnings per share for the quarter, beating analysts' consensus estimates of $0.06 by $0.01. The specialty pharmaceutical company earned $41.09 million during the quarter, compared to analyst estimates of $42.05 million. BioDelivery Sciences International had a trailing twelve-month return on equity of 21.25% and a net margin of 50.90%. During the same quarter in the prior year, the company posted $0.09 EPS.

What other stocks do shareholders of BioDelivery Sciences International own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioDelivery Sciences International investors own include TG Therapeutics (TGTX), Eldorado Gold (EGO), NVIDIA (NVDA), Inovio Pharmaceuticals (INO), Synergy Pharmaceuticals (SGYP), JD.com (JD), Baidu (BIDU), ACADIA Pharmaceuticals (ACAD), Advanced Micro Devices (AMD) and Alibaba Group (BABA).

What is BioDelivery Sciences International's stock symbol?

BioDelivery Sciences International trades on the NASDAQ under the ticker symbol "BDSI."

What is BioDelivery Sciences International's stock price today?

One share of BDSI stock can currently be purchased for approximately $5.59.

How much money does BioDelivery Sciences International make?

BioDelivery Sciences International (NASDAQ:BDSI) has a market capitalization of $577.05 million and generates $166.70 million in revenue each year. The specialty pharmaceutical company earns $84.86 million in net income (profit) each year or $0.83 on an earnings per share basis.

How many employees does BioDelivery Sciences International have?

The company employs 200 workers across the globe.

When was BioDelivery Sciences International founded?

BioDelivery Sciences International was founded in 1997.

How can I contact BioDelivery Sciences International?

BioDelivery Sciences International's mailing address is 4131 PARKLAKE AVENUE SUITE 225, RALEIGH NC, 27612. The official website for the company is www.bdsi.com. The specialty pharmaceutical company can be reached via phone at (919) 582-9050, via email at matthew@lifesciadvisors.com, or via fax at 919-582-9051.

This page (NASDAQ:BDSI) was last updated on 8/14/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.